Navigation Links
Sinobiomed Directors Confirm Hiring of New Chief Financial Officer

SHANGHAI, China, Oct. 8 /PRNewswire-FirstCall/ -- Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTC Bulletin Board: SOBM) is pleased to announce that its Board of Directors voted on October 2, 2008 to officially appoint Lionel Choong as the Company's Chief Financial Officer under a Corporate Consulting Services Agreement to be effective as of September 1, 2008. In addition, Mr. Choong has been appointed to the Company's audit committee. An earlier news release dated August 13, 2008 that first announced the hiring can be viewed on the Company website. (

As CFO, Mr. Choong will oversee the Company's various financial functions, including finance and accounting, financial planning and analysis, regulatory and risk management, and facilities development. He will also be involved with other corporate activities working with the Company's CEO, Banyun Yang, to develop strategies and tactics for long-term growth.


Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.




PHONE: 86-58993708 / FAX: 86-58993709


PHONE: 1-718-502-8801 TOLL FREE: 1-866-588-0829


FORWARD LOOKING STATEMENTS This news release may include "forward-looking

statements" regarding Sinobiomed, and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiomed expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiomed does not undertake any obligation to update any forward looking statement, except as required under applicable law.

SOURCE Sinobiomed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Launches Video Contest for Young Directors
2. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
3. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
4. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
5. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
6. Patient Safety Authority Board of Directors Names Infection Advisory Panel
7. William Moore Appointed to IRIDEX Board of Directors
8. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
9. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
10. Jon R. Wampler Joins Portico Systems Board of Directors
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology: